KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Current Deferred Revenue (2016 - 2017)

Pacira BioSciences has reported Current Deferred Revenue over the past 8 years, most recently at $102000.0 for Q4 2017.

  • Quarterly results put Current Deferred Revenue at $102000.0 for Q4 2017, down 82.86% from a year ago — trailing twelve months through Dec 2017 was $102000.0 (down 82.86% YoY), and the annual figure for FY2017 was $102000.0, down 82.86%.
  • Current Deferred Revenue for Q4 2017 was $102000.0 at Pacira BioSciences, down from $520000.0 in the prior quarter.
  • Over the last five years, Current Deferred Revenue for PCRX hit a ceiling of $1.4 million in Q2 2014 and a floor of $102000.0 in Q4 2017.
  • Median Current Deferred Revenue over the past 5 years was $1.0 million (2013), compared with a mean of $1.1 million.
  • Biggest five-year swings in Current Deferred Revenue: crashed 86.56% in 2013 and later surged 46.71% in 2014.
  • Pacira BioSciences' Current Deferred Revenue stood at $1.0 million in 2013, then skyrocketed by 41.47% to $1.4 million in 2014, then changed by 0.0% to $1.4 million in 2015, then crashed by 58.27% to $595000.0 in 2016, then tumbled by 82.86% to $102000.0 in 2017.
  • The last three reported values for Current Deferred Revenue were $102000.0 (Q4 2017), $520000.0 (Q1 2017), and $595000.0 (Q4 2016) per Business Quant data.